{ "event": { "ticker": "VNDA", "company": "Vanda Pharmaceuticals Inc.", "drug": "imsidolimab", "application_type": "BLA", "indication": "generalized pustular psoriasis (GPP)", "pdufa_date": "2026-12-12" }, "display": { "company": "Vanda", "drug": "imsidolimab", "indication_en": "generalized pustular psoriasis", "indication_zh": "泛发性脓疱型银屑病" }, "probability_approval": 0.7, "confidence": "low", "base_rate_used": 0.76, "key_factors": [ { "factor": "The pivotal trial met its primary endpoint at both doses", "direction": "+", "step": "small", "evidence": "GEMINI-1 randomized 45 adults in a GPP flare 1:1:1 to a single intravenous dose of imsidolimab 750 mg, 300 mg or placebo. At week 4, 8 of 15 patients (53.3%) on each dose were clear or almost clear (GPPPGA 0/1), against 2 of 15 (13.3%) on placebo. The sponsor reported p=0.0131 for 750 mg in 2023; the 2026 publication reports P=0.023 for each dose. The difference posted on ClinicalTrials.gov is about 40 percentage points, with 95% confidence intervals of 8.27 to 70.57 (750 mg) and 8.66 to 71.47 (300 mg).", "source": "AnaptysBio press release, 2023-10-09: https://www.sec.gov/Archives/edgar/data/1370053/000137005323000054/anaptysannouncespositive.htm; Smieszek S et al., NEJM Evidence 2026;5(5):EVIDoa2500272: https://pubmed.ncbi.nlm.nih.gov/42047557/; ClinicalTrials.gov NCT05352893 (GEMINI-1), results posted 2026-03-17: https://clinicaltrials.gov/study/NCT05352893" }, { "factor": "The evidence rests on one very small trial, and the result is statistically fragile", "direction": "-", "step": "medium", "evidence": "Each arm had 15 patients, so the efficacy claim rests on 8 responders against 2. On those counts a two-sided Fisher exact test gives a p-value of about 0.050 and an unstratified chi-square test about 0.020; one more placebo responder would lift the chi-square p-value to about 0.058 (calculated from the posted counts; the pre-specified test was a stratified Cochran-Mantel-Haenszel test). The key secondary endpoint, pustule clearance (PRS 0/1) at week 1, was reached by 6 of 15 patients (40.0%) on 750 mg against 2 of 15 (13.3%) on placebo, and the posted 95% confidence interval for the difference, -3.74 to 57.07, includes zero. The statistical plan posted with the trial tests in a fixed order (750 mg primary, 750 mg key secondary, 300 mg primary, 300 mg key secondary) and stops at the first failure, so the 300 mg results may not count as formally confirmed. The two doses gave the same week-4 response; 10 of 15 placebo patients left the trial early and became eligible for rescue treatment, and the plan counts rescued patients as non-responders; the placebo group was younger (mean age 33.3 years, against 46.8 and 48.7); and 4 of the 45 patients were enrolled in the United States.", "source": "ClinicalTrials.gov NCT05352893 (GEMINI-1), results posted 2026-03-17: https://clinicaltrials.gov/study/NCT05352893; GEMINI-1 statistical plan dated 2022-12-09, posted on ClinicalTrials.gov: https://cdn.clinicaltrials.gov/large-docs/93/NCT05352893/SAP_001.pdf; AnaptysBio press release, 2023-10-09: https://www.sec.gov/Archives/edgar/data/1370053/000137005323000054/anaptysannouncespositive.htm" }, { "factor": "FDA has already approved a drug against the same target for GPP flares on one small trial", "direction": "+", "step": "medium", "evidence": "Spevigo (spesolimab), also an antibody against the IL-36 receptor, was approved on 1 September 2022 for GPP flares on a single placebo-controlled trial of 53 patients (Effisayil-1): at week 1, 19 of 35 patients (54%) on the drug had no visible pustules, against 1 of 18 (6%) on placebo, a difference of 49 percentage points (95% CI 21 to 67). This shows that FDA accepts a single small trial in this disease, and an approved drug with the same mechanism lends biological support to imsidolimab's result. The comparison has limits: spesolimab had breakthrough therapy designation and priority review, more patients on active drug, and a larger effect seen earlier.", "source": "FDA Drug Trials Snapshot: Spevigo: https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-spevigo; Boehringer Ingelheim press release, 2021-12-15: https://www.prnewswire.com/news-releases/us-fda-grants-priority-review-for-spesolimab-for-the-treatment-of-flares-in-patients-with-generalized-pustular-psoriasis-gpp-a-rare-life-threatening-skin-disease-301444799.html" }, { "factor": "Vanda's first biologic, and the manufacturer has not been named", "direction": "-", "step": "medium", "evidence": "Vanda's approved products are all small-molecule drugs made by contract manufacturers; the company has no manufacturing facilities. Imsidolimab is a monoclonal antibody developed by AnaptysBio. Under the January 2025 licence, AnaptysBio's contract-manufacturing agreements, its existing drug supply and a GMP drug-substance batch manufacturing credit passed to Vanda, with a technology transfer planned for 2025. Neither company has publicly named the drug-substance or drug-product sites, so their FDA inspection records cannot be checked, and there is no public statement on whether FDA's pre-licence inspections have taken place. In August 2026 Vanda said commercial supply manufacturing was nearing completion.", "source": "Vanda 10-K for FY2025, filed 2026-02-12: https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/vnda-20251231.htm; Exclusive License Agreement between AnaptysBio and Vanda, 2025-01-31 (sections 3.1.1, 3.1.3, 3.1.5): https://www.sec.gov/Archives/edgar/data/1370053/000137005325000046/vandalicenseagreement-re.htm; Vanda and AnaptysBio press release, 2025-02-03: https://www.sec.gov/Archives/edgar/data/1370053/000137005325000002/anab-pressrelease2025x01.htm; Vanda 8-K exhibit 99.1, 2026-08-05: https://www.sec.gov/Archives/edgar/data/1347178/000162828026053308/vnda8-k852026exhibit991.htm" }, { "factor": "FDA set a standard review after the company asked for priority review", "direction": "-", "step": "small", "evidence": "When it submitted the application in December 2025, Vanda said it had requested priority review, which could have brought approval as early as mid-2026. The goal date FDA set, 12 December 2026, is about twelve months after submission. That matches the standard clock for a new biologic (ten months after the 60-day filing period), not the priority clock (six months). Imsidolimab has orphan drug designation (granted July 2020); there is no public record of breakthrough therapy or fast track designation. A standard review does not by itself make approval less likely, but it suggests FDA did not see a clear advance over the approved IL-36 receptor antibody.", "source": "Vanda press release, 2025-12-15: https://www.prnewswire.com/news-releases/vanda-announces-submission-of-biologics-license-application-to-the-fda-for-imsidolimab-for-the-treatment-of-generalized-pustular-psoriasis-302641858.html; Vanda press release, 2026-02-25: https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-fda-acceptance-of-biologics-license-application-filing-for-imsidolimab-for-the-treatment-of-generalized-pustular-psoriasis-302696991.html; PDUFA Reauthorization Performance Goals and Procedures FY2023-2027 (sections I.A.1 and I.B): https://www.fda.gov/media/151712/download; AnaptysBio 10-K for FY2023, filed 2024-03-11: https://www.sec.gov/Archives/edgar/data/1370053/000137005324000011/anab-20231231.htm" }, { "factor": "Re-randomized maintenance data point the same way", "direction": "+", "step": "small", "evidence": "In GEMINI-2, 16 patients who had responded in GEMINI-1 were re-randomized to monthly subcutaneous imsidolimab 200 mg or placebo. None of the 8 on imsidolimab flared and all kept a clear or almost clear score; of the 8 on placebo, 63% flared and 25% kept their response. The registry reports a log-rank p=0.0018 for time to first flare and, at week 24, a difference of 36.8 percentage points in patients with no flare (95% CI 2.9 to 70.6; p=0.0334). The numbers are very small, and the trial's primary objective was safety.", "source": "AnaptysBio press release, 2024-05-09: https://www.globenewswire.com/news-release/2024/05/09/2879216/0/en/Anaptys-Announces-Positive-Top-Line-GEMINI-2-Phase-3-Clinical-Trial-Results-of-Imsidolimab-IL-36R-in-Generalized-Pustular-Psoriasis-GPP.html; ClinicalTrials.gov NCT05366855 (GEMINI-2), results posted 2026-03-27: https://clinicaltrials.gov/study/NCT05366855; GEMINI-1 and GEMINI-2 poster, EADV 2024: https://www.anaptysbio.com/wp-content/uploads/1058_EADV2024_Reich_Imsidolimab-Ph3_Final.pdf" }, { "factor": "No safety signal in the trials reported so far", "direction": "+", "step": "small", "evidence": "In GEMINI-1 none of the 30 patients given imsidolimab had a serious adverse event; the one serious event (sepsis) was on placebo, and there were no deaths. The sponsor reported no infusion reactions and no cases of DRESS or Guillain-Barre syndrome, and 1 of 30 treated patients developed anti-drug antibodies. In GEMINI-2, with follow-up of up to 116 weeks, serious events were reported in 4 patients on open-label imsidolimab (nephrogenic anaemia, raised creatine phosphokinase, bacterial arthritis, pustular psoriasis); according to the publication none led to stopping treatment. The safety database in GPP is small: about 39 patients received the intravenous dose across the two trials.", "source": "ClinicalTrials.gov NCT05352893 (GEMINI-1), results posted 2026-03-17: https://clinicaltrials.gov/study/NCT05352893; ClinicalTrials.gov NCT05366855 (GEMINI-2), results posted 2026-03-27: https://clinicaltrials.gov/study/NCT05366855; AnaptysBio press release, 2023-10-09: https://www.sec.gov/Archives/edgar/data/1370053/000137005323000054/anaptysannouncespositive.htm; Smieszek S et al., NEJM Evidence 2026;5(5):EVIDoa2500272: https://pubmed.ncbi.nlm.nih.gov/42047557/; GEMINI-1 and GEMINI-2 poster, EADV 2024: https://www.anaptysbio.com/wp-content/uploads/1058_EADV2024_Reich_Imsidolimab-Ph3_Final.pdf" }, { "factor": "No public record that FDA agreed the trial design in advance", "direction": "-", "step": "small", "evidence": "AnaptysBio's annual report for 2023 said it had had only limited discussions with FDA about the design of its later-stage studies, and that FDA might ask for additional trials even though the company believed GEMINI-1 and GEMINI-2 would be sufficient. In February 2025 its chief executive described a pre-BLA meeting with FDA in 2024 as productive, without giving details. No special protocol assessment or other written FDA position has been disclosed.", "source": "AnaptysBio 10-K for FY2023, filed 2024-03-11: https://www.sec.gov/Archives/edgar/data/1370053/000137005324000011/anab-20231231.htm; Vanda and AnaptysBio press release, 2025-02-03: https://www.sec.gov/Archives/edgar/data/1370053/000137005325000002/anab-pressrelease2025x01.htm" }, { "factor": "The application was filed without disclosed problems, and no advisory committee is scheduled", "direction": "+", "step": "small", "evidence": "FDA accepted the application for filing in February 2026. Vanda described it as under review, with the 12 December 2026 goal date, in its quarterly report of 6 August 2026 and in a release of 24 August 2026, and AnaptysBio repeated the date in a filing of 21 September 2026. Vanda's latest release, of 2 October 2026 on conference posters, does not mention the review. As of 5 October 2026, the only 2026 meeting notice for FDA's Dermatologic and Ophthalmic Drugs Advisory Committee, for 30 October 2026, concerns a different product. Neither company has disclosed a review issue or a change to the goal date.", "source": "Vanda press release, 2026-02-25: https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-fda-acceptance-of-biologics-license-application-filing-for-imsidolimab-for-the-treatment-of-generalized-pustular-psoriasis-302696991.html; Vanda 10-Q for Q2 2026, filed 2026-08-06: https://www.sec.gov/Archives/edgar/data/1347178/000162828026053855/vnda-20260630.htm; Vanda press release, 2026-08-24: https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-granted-orphan-designation-for-imsidolimab-for-the-treatment-of-generalized-pustular-psoriasis-by-the-european-commission-302857847.html; AnaptysBio 10-KT, filed 2026-09-21: https://www.sec.gov/Archives/edgar/data/1370053/000119312526396696/anab-20260630.htm; Vanda press release, 2026-10-02: https://www.biospace.com/press-releases/vanda-pharmaceuticals-announces-presentation-at-2026-eadv-annual-meeting; Federal Register notice, 2026-09-25 (advisory committee meeting of 2026-10-30): https://www.federalregister.gov/documents/2026/09/25/2026-19700/dermatologic-and-ophthalmic-drugs-advisory-committee-notice-of-meeting-establishment-of-a-public; FDA advisory committee calendar, meeting of 2026-10-30: https://www.fda.gov/advisory-committees/advisory-committee-calendar/october-30-2026-dermatologic-and-ophthalmic-drugs-advisory-committee-meeting-announcement-10302026" }, { "factor": "The sponsor has two recent first-cycle approvals and is preparing to launch", "direction": "+", "step": "small", "evidence": "FDA approved Vanda's Nereus (tradipitant) for motion-induced vomiting on its goal date, 30 December 2025, and Bysanti (milsaperidone) on 20 February 2026, one day before its goal date. Vanda says it has been manufacturing commercial supplies of imsidolimab and now uses the brand name Quimilza. It reported $170.0 million in cash at 30 June 2026, which it expects to fund operations through at least the end of 2027, so its financing does not hinge on this decision.", "source": "Vanda 8-K exhibit 99.1, 2025-12-30: https://www.sec.gov/Archives/edgar/data/1347178/000162828025059155/vnda8-k12302025exhibit991.htm; Vanda 8-K exhibit 99.1, 2026-02-20: https://www.sec.gov/Archives/edgar/data/1347178/000162828026010376/vnda8-k2232026exhibit991.htm; Vanda 8-K exhibit 99.1, 2025-05-07: https://www.sec.gov/Archives/edgar/data/1347178/000162828025023154/vnda8-k572025exhibit991.htm; Vanda 8-K exhibit 99.1, 2026-08-05: https://www.sec.gov/Archives/edgar/data/1347178/000162828026053308/vnda8-k852026exhibit991.htm" }, { "factor": "A history of rejections and open disputes with FDA", "direction": "-", "step": "small", "evidence": "FDA issued complete response letters for Vanda's tradipitant in gastroparesis (18 September 2024) and Hetlioz in insomnia (4 March 2024). In January 2026 CDER again concluded that Hetlioz for jet lag could not be approved; a formal hearing on that application is scheduled to begin on 14 December 2026, two days after the imsidolimab goal date. Vanda is also in court against FDA over, among other things, the agency's use of review clocks longer than 180 days. These cases involve other drugs and other review divisions, and turned on efficacy evidence that FDA judged insufficient. They show that FDA has turned Vanda down when it found the evidence thin, and that the two sides remain adversaries in several proceedings.", "source": "Vanda press release, 2024-09-19: https://www.prnewswire.com/news-releases/fda-declines-to-approve-vandas-marketing-application-for-tradipitant-in-gastroparesis-302253040.html; Vanda 10-K for FY2025, filed 2026-02-12: https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/vnda-20251231.htm; Vanda 8-K exhibit 99.1, 2026-01-08: https://www.sec.gov/Archives/edgar/data/1347178/000162828026001273/vnda8-k172026exhibit991.htm; Vanda 10-Q for Q2 2026, filed 2026-08-06: https://www.sec.gov/Archives/edgar/data/1347178/000162828026053855/vnda-20260630.htm; Vanda 8-K exhibit 99.1, 2025-10-01: https://www.sec.gov/Archives/edgar/data/1347178/000162828025043489/vnda8-k1012025exhibit991.htm" } ], "manufacturing_risk": { "level": "medium", "why": "Imsidolimab would be Vanda's first biologic. Vanda has no manufacturing facilities and relies entirely on contract manufacturers; the antibody was developed by AnaptysBio, whose contract-manufacturing agreements, existing supply and manufacturing know-how were transferred to Vanda under the January 2025 licence. The drug-substance and drug-product sites have not been named publicly, so they cannot be checked for FDA Form 483 observations, warning letters or inspection classifications, and there is no public word on FDA's pre-licence inspections. Vanda said in August 2026 that commercial supply manufacturing was nearing completion. A first biologic made by undisclosed contractors after a technology transfer leaves real room for a manufacturing or inspection finding. The rating is a judgement made without knowing the sites; it cannot be made more precise from public information." }, "what_would_change_my_mind": [ "Up: Vanda discloses label negotiations or post-marketing commitments with FDA, or says the pre-licence inspections of the manufacturing sites are complete without significant findings.", "Up: the manufacturing sites are named and have clean recent FDA inspection records.", "Down: a Form 483 with significant observations, a warning letter or a failed inspection is disclosed for a site that makes imsidolimab.", "Down: FDA asks for additional clinical data or a second trial, or convenes an advisory committee.", "Down: FDA extends the goal date after a major amendment (historically not strongly negative, but a sign of open questions), or Vanda's quarterly reports soften the launch wording or stop repeating the 12 December 2026 goal date.", "Void rather than no: Vanda withdraws the application before FDA acts." ], "summary_en": "FDA approval of imsidolimab (Quimilza) for generalized pustular psoriasis in this review cycle is put at 70%, below the 76% base rate for first-time applications from smaller companies. The pivotal trial met its primary endpoint: 53% of patients were clear or almost clear at week 4, against 13% on placebo, and in 2022 FDA approved a drug against the same target on one small trial. But each arm had only 15 patients, FDA set a standard review after Vanda asked for priority review, and this is Vanda's first biologic, made by contractors it has not named. No FDA view of the application is public, so confidence is low.", "summary_zh": "FDA 在本轮审评中批准 imsidolimab（Quimilza）用于泛发性脓疱型银屑病的概率估计为 70%，低于小公司首次申请 76% 的基准。关键试验达到主要终点：第 4 周皮损清除或几乎清除的患者占 53%，安慰剂组为 13%；FDA 在 2022 年也曾凭一项小型试验批准过同靶点药物。但每组只有 15 名患者；Vanda 申请了优先审评，FDA 给的却是标准审评；这还是 Vanda 的第一个生物制品，由未公开名称的代工厂生产。FDA 对这份申请的看法没有任何公开信息，因此把握度低。", "sources": [ "Vanda press release, 2026-02-25: https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-fda-acceptance-of-biologics-license-application-filing-for-imsidolimab-for-the-treatment-of-generalized-pustular-psoriasis-302696991.html", "Vanda press release, 2025-12-15: https://www.prnewswire.com/news-releases/vanda-announces-submission-of-biologics-license-application-to-the-fda-for-imsidolimab-for-the-treatment-of-generalized-pustular-psoriasis-302641858.html", "Vanda 10-Q for Q2 2026, filed 2026-08-06: https://www.sec.gov/Archives/edgar/data/1347178/000162828026053855/vnda-20260630.htm", "Vanda 8-K exhibit 99.1, 2026-08-05: https://www.sec.gov/Archives/edgar/data/1347178/000162828026053308/vnda8-k852026exhibit991.htm", "Vanda 8-K exhibit 99.1, 2026-05-06: https://www.sec.gov/Archives/edgar/data/1347178/000162828026031241/vnda8-k562026exhibit991.htm", "Vanda 10-K for FY2025, filed 2026-02-12: https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/vnda-20251231.htm", "AnaptysBio 10-KT, filed 2026-09-21: https://www.sec.gov/Archives/edgar/data/1370053/000119312526396696/anab-20260630.htm", "AnaptysBio 10-K for FY2023, filed 2024-03-11: https://www.sec.gov/Archives/edgar/data/1370053/000137005324000011/anab-20231231.htm", "Exclusive License Agreement between AnaptysBio and Vanda, 2025-01-31 (sections 3.1.1, 3.1.3, 3.1.5): https://www.sec.gov/Archives/edgar/data/1370053/000137005325000046/vandalicenseagreement-re.htm", "Vanda and AnaptysBio press release, 2025-02-03: https://www.sec.gov/Archives/edgar/data/1370053/000137005325000002/anab-pressrelease2025x01.htm", "AnaptysBio press release, 2023-10-09: https://www.sec.gov/Archives/edgar/data/1370053/000137005323000054/anaptysannouncespositive.htm", "AnaptysBio press release, 2024-05-09: https://www.globenewswire.com/news-release/2024/05/09/2879216/0/en/Anaptys-Announces-Positive-Top-Line-GEMINI-2-Phase-3-Clinical-Trial-Results-of-Imsidolimab-IL-36R-in-Generalized-Pustular-Psoriasis-GPP.html", "ClinicalTrials.gov NCT05352893 (GEMINI-1), results posted 2026-03-17: https://clinicaltrials.gov/study/NCT05352893", "GEMINI-1 statistical plan dated 2022-12-09, posted on ClinicalTrials.gov: https://cdn.clinicaltrials.gov/large-docs/93/NCT05352893/SAP_001.pdf", "ClinicalTrials.gov NCT05366855 (GEMINI-2), results posted 2026-03-27: https://clinicaltrials.gov/study/NCT05366855", "Smieszek S et al., NEJM Evidence 2026;5(5):EVIDoa2500272: https://pubmed.ncbi.nlm.nih.gov/42047557/", "GEMINI-1 and GEMINI-2 poster, EADV 2024: https://www.anaptysbio.com/wp-content/uploads/1058_EADV2024_Reich_Imsidolimab-Ph3_Final.pdf", "FDA Drug Trials Snapshot: Spevigo: https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-spevigo", "Boehringer Ingelheim press release, 2021-12-15: https://www.prnewswire.com/news-releases/us-fda-grants-priority-review-for-spesolimab-for-the-treatment-of-flares-in-patients-with-generalized-pustular-psoriasis-gpp-a-rare-life-threatening-skin-disease-301444799.html", "PDUFA Reauthorization Performance Goals and Procedures FY2023-2027 (sections I.A.1 and I.B): https://www.fda.gov/media/151712/download", "Federal Register notice, 2026-09-25 (advisory committee meeting of 2026-10-30): https://www.federalregister.gov/documents/2026/09/25/2026-19700/dermatologic-and-ophthalmic-drugs-advisory-committee-notice-of-meeting-establishment-of-a-public", "FDA advisory committee calendar, meeting of 2026-10-30: https://www.fda.gov/advisory-committees/advisory-committee-calendar/october-30-2026-dermatologic-and-ophthalmic-drugs-advisory-committee-meeting-announcement-10302026", "Vanda 8-K exhibit 99.1, 2025-12-30: https://www.sec.gov/Archives/edgar/data/1347178/000162828025059155/vnda8-k12302025exhibit991.htm", "Vanda 8-K exhibit 99.1, 2026-02-20: https://www.sec.gov/Archives/edgar/data/1347178/000162828026010376/vnda8-k2232026exhibit991.htm", "Vanda 8-K exhibit 99.1, 2025-05-07: https://www.sec.gov/Archives/edgar/data/1347178/000162828025023154/vnda8-k572025exhibit991.htm", "Vanda press release, 2024-09-19: https://www.prnewswire.com/news-releases/fda-declines-to-approve-vandas-marketing-application-for-tradipitant-in-gastroparesis-302253040.html", "Vanda 8-K exhibit 99.1, 2026-01-08: https://www.sec.gov/Archives/edgar/data/1347178/000162828026001273/vnda8-k172026exhibit991.htm", "Vanda 8-K exhibit 99.1, 2025-10-01: https://www.sec.gov/Archives/edgar/data/1347178/000162828025043489/vnda8-k1012025exhibit991.htm", "Vanda press release, 2026-08-24: https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-granted-orphan-designation-for-imsidolimab-for-the-treatment-of-generalized-pustular-psoriasis-by-the-european-commission-302857847.html", "Vanda press release, 2026-10-02: https://www.biospace.com/press-releases/vanda-pharmaceuticals-announces-presentation-at-2026-eadv-annual-meeting" ], "zh": { "indication": "泛发性脓疱型银屑病（GPP）", "key_factors": [ { "factor": "关键试验在两个剂量上都达到了主要终点", "evidence": "GEMINI-1 把 45 名处于 GPP 发作期的成人按 1:1:1 随机分组，单次静脉给予 imsidolimab 750 mg、300 mg 或安慰剂。第 4 周时，两个剂量组各有 15 人中的 8 人（53.3%）皮损清除或几乎清除（GPPPGA 0/1），安慰剂组为 15 人中的 2 人（13.3%）。申办方 2023 年公布 750 mg 组 p=0.0131；2026 年发表的论文报告两个剂量均为 P=0.023。ClinicalTrials.gov 登记的组间差约为 40 个百分点，95% 置信区间分别为 8.27 至 70.57（750 mg）和 8.66 至 71.47（300 mg）。" }, { "factor": "证据只来自一项很小的试验，统计结果并不稳固", "evidence": "每组只有 15 名患者，疗效结论靠的是 8 名应答者对 2 名。按这些例数计算，双侧 Fisher 精确检验的 p 值约为 0.050，不分层卡方检验约为 0.020；安慰剂组只要再多 1 名应答者，卡方检验的 p 值就升到约 0.058（以上按登记的例数计算；预先设定的是分层 Cochran-Mantel-Haenszel 检验）。关键次要终点是第 1 周脓疱清除（PRS 0/1）：750 mg 组 15 人中 6 人（40.0%）达到，安慰剂组 15 人中 2 人（13.3%），登记的组间差 95% 置信区间为 -3.74 至 57.07，包含零。随试验公开的统计分析计划规定按固定顺序检验（750 mg 主要终点、750 mg 关键次要终点、300 mg 主要终点、300 mg 关键次要终点），一旦失败即停止，因此 300 mg 的结果未必算得上正式确证。两个剂量第 4 周的应答率相同；安慰剂组 15 人中有 10 人提前退出并可接受补救治疗，而按分析计划，接受补救治疗的患者计为无应答；安慰剂组更年轻（平均 33.3 岁，另两组为 46.8 岁和 48.7 岁）；45 名患者中只有 4 名在美国入组。" }, { "factor": "FDA 已凭一项小型试验批准过同靶点药物治疗 GPP 发作", "evidence": "Spevigo（spesolimab）同样是针对 IL-36 受体的抗体，2022 年 9 月 1 日获批用于 GPP 发作，依据是一项 53 名患者的安慰剂对照试验（Effisayil-1）：第 1 周时，用药组 35 人中 19 人（54%）无可见脓疱，安慰剂组 18 人中 1 人（6%），差值 49 个百分点（95% CI 21 至 67）。这说明 FDA 在这种疾病上接受单项小型试验，同机制药物已获批也为 imsidolimab 的结果提供了生物学上的佐证。可比性有限：spesolimab 有突破性疗法认定并获优先审评，用药组人数更多，疗效更大且出现得更早。" }, { "factor": "这是 Vanda 的第一个生物制品，生产厂没有公开", "evidence": "Vanda 已获批的产品都是小分子药物，由合同生产商生产，公司自己没有生产设施。imsidolimab 是 AnaptysBio 开发的单克隆抗体。根据 2025 年 1 月的许可协议，AnaptysBio 的合同生产协议、现有药品库存和一笔 GMP 原液批次生产额度转给了 Vanda，技术转移计划在 2025 年进行。两家公司都没有公开原液和制剂的生产场地，因此无从查核这些场地的 FDA 检查记录，也没有关于 FDA 批准前检查是否已经进行的公开说法。2026 年 8 月 Vanda 表示商业化供货的生产接近完成。" }, { "factor": "公司申请了优先审评，FDA 给的是标准审评", "evidence": "2025 年 12 月提交申请时，Vanda 表示已申请优先审评，若获准最早可在 2026 年年中获批。FDA 定下的目标日期是 2026 年 12 月 12 日，距提交约 12 个月，对应的是新生物制品的标准审评时限（60 天立卷期后 10 个月），而不是优先审评时限（6 个月）。imsidolimab 有孤儿药认定（2020 年 7 月授予）；公开资料未见突破性疗法或快速通道认定。标准审评本身并不降低获批的可能，但说明 FDA 没有认定它比已获批的 IL-36 受体抗体有明显进步。" }, { "factor": "再随机的维持治疗数据方向一致", "evidence": "在 GEMINI-2 中，GEMINI-1 的 16 名应答者被再次随机分组，每月皮下注射 imsidolimab 200 mg 或安慰剂。imsidolimab 组 8 人无一复发，全部维持清除或几乎清除；安慰剂组 8 人中 63% 复发，25% 维持应答。登记结果显示，至首次复发时间的 log-rank 检验 p=0.0018；第 24 周无复发患者比例的差值为 36.8 个百分点（95% CI 2.9 至 70.6；p=0.0334）。例数极少，而且该试验的主要目的是评价安全性。" }, { "factor": "目前公布的试验未见安全性信号", "evidence": "GEMINI-1 中接受 imsidolimab 的 30 名患者无一发生严重不良事件；唯一的严重事件（脓毒症）发生在安慰剂组，无死亡。申办方称未见输液反应，也没有 DRESS 或吉兰-巴雷综合征病例，30 名用药患者中 1 人出现抗药抗体。GEMINI-2 随访最长 116 周，开放标签 imsidolimab 组有 4 名患者报告严重事件（肾性贫血、肌酸磷酸激酶升高、细菌性关节炎、脓疱型银屑病）；论文称无一导致停药。GPP 的安全性数据库很小：两项试验中约 39 名患者接受过静脉给药。" }, { "factor": "公开资料未见 FDA 事先认可试验设计", "evidence": "AnaptysBio 在 2023 年年报中说，它与 FDA 就后期研究的设计只有有限的讨论；虽然公司认为 GEMINI-1 和 GEMINI-2 足以支持获批，FDA 仍可能要求追加试验。2025 年 2 月，其首席执行官称 2024 年与 FDA 的 pre-BLA 会议富有成效，但没有给出细节。没有披露特殊方案评估（SPA）或其他书面的 FDA 意见。" }, { "factor": "申请立卷时未披露问题，也没有安排咨询委员会", "evidence": "FDA 于 2026 年 2 月受理该申请。Vanda 在 2026 年 8 月 6 日的季度报告和 2026 年 8 月 24 日的新闻稿中都称申请仍在审评中，PDUFA 目标日期为 2026 年 12 月 12 日；AnaptysBio 在 2026 年 9 月 21 日的文件中也重申了这一日期。Vanda 最近一份新闻稿（2026 年 10 月 2 日，内容是学术会议壁报）没有提到审评。截至 2026 年 10 月 5 日，FDA 皮肤与眼科药物咨询委员会 2026 年唯一的会议通知是 2026 年 10 月 30 日那一场，讨论的是另一个产品。两家公司都没有披露审评中出现的问题或目标日期的变动。" }, { "factor": "申办方近期有两次首轮获批，并在为上市做准备", "evidence": "FDA 于 2025 年 12 月 30 日（目标日期当天）批准了 Vanda 的 Nereus（tradipitant）用于预防运动引起的呕吐，又于 2026 年 2 月 20 日批准了 Bysanti（milsaperidone），比目标日期早一天。Vanda 表示一直在生产 imsidolimab 的商业化供货，并已启用商品名 Quimilza。公司称截至 2026 年 6 月 30 日持有现金 $170.0 million，预计可支撑运营至少到 2027 年底，因此其资金并不取决于这次审评结果。" }, { "factor": "有被拒的前例，与 FDA 的争议仍未了结", "evidence": "FDA 曾就 Vanda 的 tradipitant 胃轻瘫适应症（2024 年 9 月 18 日）和 Hetlioz 失眠适应症（2024 年 3 月 4 日）发出完全回应函（CRL）。2026 年 1 月，CDER 再次认定 Hetlioz 时差适应症不能获批；针对该申请的正式听证定于 2026 年 12 月 14 日开始，也就是 imsidolimab 的 PDUFA 目标日期两天之后。Vanda 还就多项事由起诉 FDA，其中包括 FDA 采用超过 180 天的审评时限。这些案件涉及别的药物和别的审评部门，争议点是 FDA 认为不充分的疗效证据。它们说明，FDA 认为证据单薄时会拒绝 Vanda，双方在多项程序中仍处于对立状态。" } ], "manufacturing_risk_why": "imsidolimab 将是 Vanda 的第一个生物制品。Vanda 没有生产设施，完全依赖合同生产商；该抗体由 AnaptysBio 开发，其合同生产协议、现有库存和生产技术根据 2025 年 1 月的许可协议转给了 Vanda。原液和制剂的生产场地没有公开，因此无法查核这些场地是否有 FDA 483 表观察项、警告信或检查分级记录，FDA 批准前检查的情况也没有公开信息。Vanda 在 2026 年 8 月表示商业化供货的生产接近完成。第一个生物制品，由未公开的代工厂在技术转移之后生产，出现生产或检查问题的余地不小。这一评级是在不知道生产场地的情况下作出的判断，凭公开信息无法更精确。", "what_would_change_my_mind": [ "上调：Vanda 披露正与 FDA 商谈说明书或上市后承诺，或表示生产场地的批准前检查已经完成且没有重大发现。", "上调：生产场地公开，且近期的 FDA 检查记录良好。", "下调：生产 imsidolimab 的某个场地被披露收到含重大观察项的 483 表、警告信，或未通过检查。", "下调：FDA 要求补充临床数据或追加一项试验，或召开咨询委员会。", "下调：FDA 因重大补充资料而延后目标日期（历史上并非强烈的负面信号，但说明仍有悬而未决的问题），或 Vanda 的季度报告淡化上市准备的措辞、不再重申 2026 年 12 月 12 日的 PDUFA 目标日期。", "作废而非否决：Vanda 在 FDA 作出决定前撤回申请。" ] }, "recorded_at": "2026-10-05T08:21:32+00:00" }